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Aberrant expression of Eph and ephrin proteins has well-established functions in oncogenesis and tumour progression. We describe
EphA1 expression in 6 colorectal cancer (CRC) cell lines, 18 controls and 125 CRC specimens. In addition, a well-characterised
cohort of 53 paired normal colon and CRCs was also assessed. Expression of EphA1 mRNA was assessed by quantitative real-time
PCR and correlated with protein expression by flow cytometry, immunoprecipitation, western blotting and immunohistochemistry.
Significant upregulation (2- to 10-fold) of EphA1 was seen in over 50% of cases (P¼0.005) whereas many of the remainder showed
downregulation of EphA1. Intriguingly, EphA1 over-expression was more prevalent in stage II compared to stage III CRCs (P¼0.02).
Low EphA1 expression significantly correlated with poor survival (P¼0.02). Epigenetic silencing appeared to explain the loss of
EphA1 expression as methylation of the EphA1 CpG island strongly correlated with low EphA1 expression (Po0.01). Furthermore,
EphA1 re-expression could be induced by treatment with demethylating agents. Our findings identify EphA1 as a potential prognostic
marker in CRC. Although therapies targeting high EphA1 expression seem plausible in CRC, the loss of expression in advanced
disease suggests a potential risk that targeted therapy, by selecting for loss of expression, might contribute to disease progression.
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The 16 vertebrate Eph receptors (EphA1–10, EphB1–6) form the
largest subfamily of receptor tyrosine kinases. Activation of
signalling by these receptors is mediated by interaction with nine
cell-surface counter receptors known as ephrins. Eph receptors are
divided into two classes, A and B, based on structural features of
their ligand-binding domains and preferential binding to either
ephrins A1–6 or ephrins B1–3 groups, respectively (Boyd and
Lackmann, 2001). The ephrin A ligands are bound to the cell
surface by a glycosyl phosphatidylinositol anchor and bind to class
A receptors, whereas the ephrin B ligands are type I transmem-
brane proteins and bind to class B receptors (Gale et al, 1996).
Eph–ephrin interactions are known to mediate both pro-
adhesive and anti-adhesive signals in both normal and tumour
cells and also have a function in tumour angiogenesis (Adams,
2002; Wilkinson, 2003). High Eph and ephrin expression has been
reported in many human cancers including various carcinomas,
melanoma, sarcoma, kidney and brain tumours (Dodelet and
Pasquale, 2000; Nakamoto and Bergemann, 2002; Brantley-Sieders
et al, 2004). EphB and ephrin B proteins have been implicated in
both normal and malignant epithelial tissues. Signalling through
EphB2/B3 and ephrin B ligands regulates cell sorting in the mature
gut epithelium (Batlle et al, 2002; Sancho et al, 2003). Over-
expression of EphB2, EphB4 and ephrin B1 has been described in
gastric, colon and breast cancers (Stephenson et al, 2001; Berclaz
et al, 2002; Kataoka et al, 2002). Interestingly, over-expression of
ephrin B2 in colorectal cancers (CRCs) appears to correlate
with increased tumour angiogenesis, unexpectedly resulting in
reduced tumour growth as new vessels were malformed (Liu et al,
2002, 2004).
Although the EphA/ephrin A system has also been implicated
in epithelial tissue structure and function, there is less data
on EphA/ephrin A expression in gut and CRC (Maru et al,
1990; Saito et al, 2004). EphA1, originally isolated as an amplified
gene in a carcinoma cell line (Hirai et al, 1987), is preferentially
expressed in epithelial cells. Ephrin A1 is the highest affinity
binding ligand for EphA1 (Coulthard et al, 2001), although it
also binds ephrin A3 and A4 with lower affinity. In mice, EphA1
is expressed in many epithelial tissues including skin, kidney,
liver and thymus (Coulthard et al, 2001). Over-expression of
human EphA1 has been observed in prostate, gastric and colon
carcinomas (Hirai et al, 1987; Maru et al, 1990; Robinson et al,
1996; Kao et al, 2003). More recently, significant downregulation of
EphA1 was reported in non-melanoma skin cancers (Hafner et al,
2006).
Despite a few reports of aberrant expression of EphA1 in CRCs,
the prevalence of EphA1 expression and its potential prognostic
and therapeutic function in CRC has not been examined system-
atically. We describe the expression of EphA1 in a series of CRC
cell lines, clinical CRC samples and a well-characterised cohort of
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spaired normal and CRC samples using quantitative real-time PCR.
We show significant EphA1 over-expression in CRCs compared to
controls. Interestingly, investigation of paired normal and CRC
samples revealed significant EphA1 over-expression in locally
invasive CRC (stage II) but also downregulation in metastatic CRC
(stage III). Further, there is evidence for active selection against
expression in metastatic lesions, mediated through epigenetic gene
silencing. Intriguingly, low EphA1 expression correlated with
shortened survival. The potential consequences of this on colon
cancer cell biology are discussed.
MATERIALS AND METHODS
Cell lines and clinical samples
Six CRC cell lines (LIM1215, CaCo2, LISP-1, LOVO, HCT116 and
HT29) were cultured in RPMI 1640 medium with 10% fetal bovine
serum (FBS). CaCo2 was cultured in Dulbecco’s modified medium
(Gibco, Mount Waverley, VIC, Australia) with 20% FBS. Lines were
maintained in a 5% CO2 humidified incubator at 371C. A total of
196 colon specimens were assessed in this study, including colon
tissue qPCR arrays (OriGene Technologies, Rockville, MD, USA)
consisting of 143 cDNA samples and a well-characterised cohort of
53 paired normal and CRC specimens. The qPCR arrays contained
cDNA from 18 normal colon, 21 stage I, 40 stage II, 43 stage III and
21 stage IV CRC samples. The median age of the patients was
70 years (range 31–93 years) with a male/female ratio of 73:70.
The 53 paired tumour and adjacent non-malignant samples were
obtained from the Princess Alexandra Hospital tissue bank and the
Royal Brisbane Hospital (Brisbane, Australia). Stages II and III
were predominant in this cohort with only four stage I and three
stage IV cancers (Supplementary Table 1). The median age of the
patients was 72 years (range 29–84 years) with a male/female ratio
of 28:25. Additional clinical details are presented in Supplemen-
tary Table 1. All patient samples were obtained after specific
informed consent procedures were approved by the institutional
ethics committees of the relevant institutions.
RNA extraction and cDNA synthesis
Total RNA was isolated using the RNeasy Mini kits (Qiagen,
Doncaster, VIC, Australia), according to the manufacturer’s
instructions. RNA quality was assessed by agarose gel electro-
phoresis. Before cDNA synthesis, samples were treated with RQ1
RNase-free DNase I (Promega, Sydney, NSW, Australia) and first
strand cDNA was synthesised by reverse transcription using
Superscript III Reverse Transcriptase (Invitrogen, Mount Waverley,
VIC, Australia), according to the manufacturer’s instructions.
Relative quantitation by real-time PCR
Protocol for real-time PCR is described in Supplementary
methods.
Immunoprecipitation and western analysis
Protocols for immunoprecipitation and western analysis are
described in Supplementary methods.
Immunohistochemistry
The protocol for immunohistochemistry is described in Supple-
mentary methods.
Methylation analysis
Sodium bisulfite modification Genomic DNA was subjected
to sodium bisulfite modification using the CpGenome DNA
modification kit (Chemicon, Sydney, NSW, Australia) to convert
the unmethylated cytosines to uracil.
Bisulfite genomic sequencing Methylation status of the 50-CG-rich
region and the EphA1 CpG island was determined through bisulfite
sequencing and melt curve analyses. EphA1 50 UTR primers were:
50-TTTAAGGAGGTGAATTAGGTGA-30 (sense) and 50-CCATAAC
TCCGAACCGAAAC-30 (antisense). PCR was conducted in a final
volume of 25ml including 1  PCR buffer, 80ng of bisulfite-
modified DNA, 3mM Mg
2þ, of each primer, 3.2mM dNTP and 2 M
betaine. PCR products were generated using a touchdown PCR
cycle with annealing temperatures decreasing 0.51C per cycle from
68 to 601C.
For the EphA1 CpG island, bisulfite-modified genomic DNA
samples were amplified using double nested oligonucleotides (the
primer sequences were designed based on the http://www.
mdanderson.org/leukemia/methylation/bpcr.html website). These
primer sets were specific to modified templates with no CpG sites
in their sequences, therefore, both methylated and unmethylated
templates were amplified. EphA1 CpG island primers were F1 –
50-GGTGTTGGTTTTTGGGGTTA-30 and R1 – 50-AAAATTCCCTCC
CCACTCC-30. Nested primers were F2 – 50-GGTTAGGGTTGGTGT
TGTTGTT-30 and R2 – 50-AAAACCAAAAATAAACCTAACAAT-30.
PCR was performed in a final volume of 25ml including 80ng of
bisulfite-modified DNA, 10  buffer, 3mM Mg
2þ, 0.4mM of each
primer, 3.2mM dNTP and 2 M betaine. Initial amplification was
carried out using touchdown PCR from 68 to 601C. The second
round was performed in a final volume of 25ml with 2.5ml of the
primary PCR template as described above. PCR was conducted at
951C for 30s, 501C for 30s and 721C for 30s for 35 cycles followed
by a final extension at 721C for 10min.
Twenty paired normal and CRC samples for the 50-CG-rich
region and 37 paired normal and CRC samples for the CpG island
were screened through sequencing. PCR products were cloned
into the pGEM-T Easy vector (Promega) following agarose gel
purification and 10 individual clones were sequenced from each
sample. The percentage of methylation was calculated by dividing
the number of CpG sites methylated with the total number of CpG
sites assessed.
In-tube DNA melting profile A total of 21 paired normal and CRC
samples were assessed by fluorescence melting curve analysis as
described previously (Worm et al, 2001). DNA with no methyla-
tion of the target gene and DNA with complete methylation (using
Sss1 methyltransferase to methylate all cytosine residues) were
used as negative and positive controls, respectively. Of the 21
paired normal and CRC samples, 5 were also subjected to bisulfite
sequencing to ensure that the results were comparable.
PCR products were generated using a block thermocycler as
described previously. PCR product (15ml) was mixed with 5mlo f
H2O and 10ml of Quantitect SYBR Green PCR Master Mix
(Qiagen). DNA melting curves were acquired on the Rotor-Gene
3000 by measuring the fluorescence of SYBR Green I during a
linear temperature transition from 70 to 951C with a ramp of
0.51Cs
 1.
In vitro demethylation and histone deacetylase inhibition
To assess whether EphA1 expression could be restored, we treated
cell lines with a methyltransferase inhibitor with or without a
histone deacetylase (HDAC) inhibitor. A total of 4 10
5 cells were
plated into Petri dishes and treated with freshly prepared 2mM
50-aza-20-deoxycytidine (Sigma, Castle Hill, NSW, Australia) with
or without the HDAC inhibitor, suberic bishydroxamate (SBHA) at
a final concentration of 30mgml
 1. Cells were treated for periods
of 24, 48 and 72h with media and inhibitors replaced every 24h.
Cells were harvested at approximately 80% confluence after the
completion of the treatments. Quantitative PCR and bisulfite
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ssequencing were performed using RNA and DNA, respectively, as
described above. Flow cytometry was used to confirm protein
expression. All drug assays were performed in duplicate for
reproducibility.
Flow cytometry
The protocol for flow cytometry is described in Supplementary
methods.
Statistical analysis
Quantitative gene expression data from tissue arrays and paired
normal and CRC samples were initially analysed using the non-
parametric Mann–Whitney U-test and Kruskal–Wallis test. To
enable the adjustment for covariates such as age and gender, we
transformed expression data into quartiles and analysed using
binary logistic regression (response variable: tumour/no tumour).
Expression data from paired normal and CRC samples were
also analysed using the Kaplan–Meier and Cox proportional
hazards methods. Final statistical models were adjusted for patient
characteristics such as age, gender, type, site and stage. All
statistical analyses were performed using SPSS for Windows
version 15.0, and a P-value of o0.05 was considered statistically
significant. Where appropriate, a Bonferroni adjustment was
applied to P-values.
RESULTS
EphA1 expression in CRC cell lines
Quantitative PCR analysis revealed a diversity of EphA1 mRNA
expression in CRC cell lines, with lines showing high (LIM1215,
LOVO), moderate (CaCo2, HCT116, LISP1) and low expression
(HT29) (Figure 1A). Protein expression was examined by
immunoprecipitation and western blotting. EphA1 was expressed
as a single protein of the expected size (B120kDa) (Figure 1B)
and was shown to correlate well with mRNA expression. The
correlation of mRNA with protein expression was further
confirmed by analysis of EphA1 protein by flow cytometry
(Figure 1C).
EphA1 expression in colon tissue qPCR arrays
In keeping with the cell line data, heterogeneous EphA1 expression
was also observed in CRC samples. Overall, despite this hetero-
geneity, when the pooled CRC results were compared with normal
colon specimens, EphA1 expression was significantly higher in
CRCs compared to the controls (P¼0.005) (Figure 2). Interest-
ingly, this difference was only apparent in men (P¼0.003). Using
binary logistic regression to estimate the risk of normal control
tissues progressing to a CRC, we identified an approximate twofold
rise in risk per quartile increase in EphA1 expression (P¼0.01,
OR¼1.94, CI¼1.19–3.40).
Although a majority of CRCs showed upregulation of EphA1, a
cohort of CRCs also demonstrated downregulation compared to
normal colon specimens (Figure 2). No correlations were seen
between EphA1 expression, stage, grade or age.
EphA1 expression in CRC clinical samples
To further examine the heterogeneity of EphA1 expression, we
analysed 53 cases in which both normal and CRC tissues had been
obtained from each patient. Again, heterogeneous EphA1 expres-
sion was observed, with 2- to 10-fold upregulation compared with
paired normal colon in 52% of tumours. Interestingly, markedly
reduced levels of EphA1 expression compared with paired normal
colon were observed in 42% of CRCs. Of these CRCs, 10 cases
were more than 5- to 10-fold downregulated compared to the
paired normal control. Intriguingly, EphA1 downregulation was
significantly more common in stage III compared to stage II CRCs,
most of which over-expressed EphA1 mRNA (P¼0.02) (Figure 3).
Patients with low EphA1 expressing CRCs had significantly lower
survival than those with high EphA1 expressing CRCs after
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Figure 1 EphA1 mRNA and protein expression in colorectal cancer (CRC) cell lines. (A) EphA1 transcript levels normalised to 1000 copies of b-actin
quantitated by qPCR. (B) EphA1 protein expression in LIM1215 and LOVO cell lines determined through immunoprecipitation followed by western blot
analysis using an in-house rabbit anti-EphA1 antibody. (C) EphA1 protein levels determined by flow cytometry analysis. Fluorescence resulting from EphA1
protein expression (shaded) is shown relative to the secondary-only control cells. The median fluorescence value is shown.
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sadjusting for age, gender and stage (P¼0.02, RR¼1.7, 95%
CI¼1.0–2.8) (Figure 4). EphA1 expression was independent of
age, gender, tumour type and grade, although overall survival was
marginally better in women compared to men (Po0.05).
Immunohistochemistry
Immunohistochemistry for EphA1 was assessed in the 53 CRCs
and paired normal tissue. In normal colonic epithelium, stronger
membrane staining was observed at the surface epithelium and
was absent at the base of the crypt. In the corresponding CRCs,
membrane EphA1 expression was observed with varying degrees
of cytoplasmic expression (Supplementary Figure 1). Overall,
immunohistochemistry data showed a good correlation with
EphA1 mRNA expression in the clinical samples (Supplementary
Table 3).
EphA1 promoter methylation inversely correlates with
EphA1 expression in CRC
Although many reports (Hirai et al, 1987; Maru et al, 1990;
Robinson et al, 1996; Kao et al, 2003) have shown upregulation of
EphA1 in CRCs, and more recently downregulation, mechanisms
of downregulation have not been examined (Hafner et al, 2006). In
seeking a mechanism for EphA1 downregulation, epigenetic
silencing due to methylation analysis of a CpG island in the
EphA1 gene was investigated.
Analysis of the human EphA1 gene on the http://www.ebi.ac.uk/
emboss/cpgplot/ website using the accepted definition of a CpG
island (X200bp with a CþG content 450% and an observed
CpG/expected CpG 40.6) (Gardiner-Garden and Frommer, 1987)
was performed (Supplementary Figures 2 and 3). We identified a
251bp CpG island starting 13bp downstream of the translation
start site (A of the ATG¼þ1) that spans exon 1 and intron 1 of
the EphA1 gene and contained 22 CpG sites (Figure 5). A 153bp
CG-rich region immediately upstream of the translation start
site, encompassing the 50 UTR region and proximal promoter
region, contained 14 CpG sites but did not satisfy the criteria of a
CpG island.
Initial screening of the 50-CG-rich region through bisulfite
sequencing revealed consistent methylation of CpG sites 12–14
(Figure 5) in all CRC and corresponding normal samples.
Methylation of these sites was present regardless of the level of
EphA1 mRNA expression, suggesting that this region is not
involved in gene regulation. However, this provided a useful
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Figure 3 Gene expression level of EphA1 in (A) stage II and (B) stage III
colorectal cancer (CRC) samples. Expression is shown relative to its paired
normal sample.
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Figure 4 Unadjusted Kaplan–Meier survival curves from the date of
diagnosis for patients with high (m) and low (k) levels of EphA1 expression.
Follow-up time, from the date of diagnosis to the date of last review for
patients still living, is represented by the þ symbol.
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Figure 2 EphA1 mRNA expression in quantitative PCR (qPCR) colon
tissue arrays. EphA1 transcript levels normalised to 1000 copies of b-actin.
The horizontal bars represent the mean and the standard error of the
mean.
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sinternal control for assessment of the effect of methylation on gene
expression in this region.
Preliminary sequencing of the CpG island using bisulphite-
treated DNA from 37 paired normal and CRC samples established
that the average rate of methylation in these samples was 20.4%.
We employed melting profile analysis as a means to assay for
methylation status. To establish a baseline, we used the CRC cell
line LIM1215 expressing high levels of EphA1. Bisulfite sequencing
of LIM1215 established that there was no detectable methylation of
the EphA1 CpG island in this cell line. Conversely, when treated
with Sss1 methyltransferase, the EphA1 CpG island was completely
methylated in this cell line. These samples were used as negative
and positive controls in each run (Supplementary Figure 4A).
Using a dilution series, it was established that the presence of
greater than 20% methylation results in a shift of the curve
(Supplementary Figure 4B). On the basis of the average rate of
methylation observed through bisulfite sequencing data and melt
curve analysis, we found that a case was considered methylated if
the level of methylation was greater than 20% and unmethylated if
the level was less than 20%.
Methylation of EphA1 was observed in 26 out of 53 (49%) of
CRCs. Methylation was also detected in 15 cases of non-malignant
colon tissue. No methylation was detected in 21 out of 53 (40%)
cases. In keeping with a function in silencing gene expression,
methylation was more widespread in patients displaying down-
regulation of the gene (Po0.01) (Supplementary Figure 5A).
Intriguingly, methylation was significantly higher at the 30 end of
the CpG island (CpG sites 11–22) compared to the entire CpG
island (Po0.01) (Supplementary Figure 5B). An inverse correla-
tion was identified between overall methylation and EphA1
expression (r¼ 0.3); however, the correlation coefficient was
stronger when compared to the 30 end of the CpG island (r¼ 0.6).
A strong positive correlation was also evident between increased
EphA1 expression and the absence of methylation (r¼0.7).
Our studies did not attempt to elucidate whether loss of EphA1
expression was due to biallelic methylation or a combination of
methylation and allelic loss. Further examination of bisulfite
sequences of the few cases over-expressing EphA1 in the presence
of methylation revealed that methylation was primarily present at
the 50 end of the CpG island and not the 30 end of the island where
methylation was primarily detected in low expressing CRCs.
50-Aza-20-deoxycytidine treatment and SBHA treatment of
CRC cell lines
Direct evidence that methylation influences EphA1 expression was
obtained by demonstrating that 50-aza-20-deoxycytidine treatment
restored expression in HT29, and increased expression in LISP1
and HCT116 cells (Figure 6 – data shown for HT29). EphA1 mRNA
expression, methylation status and protein expression were
examined through qPCR, bisulfite sequencing and flow cytometry,
respectively. Following 50-aza-20-deoxycytidine treatment, EphA1
underwent complete demethylation at CpG sites 1–22 (Figure 6A)
and was accompanied by re-expression of the gene (Figure 6B and
C). Because methylated DNA binds methylcytosine binding
proteins that in turn interact with HDAC, the cells also were
treated with the HDAC inhibitor, SBHA, in combination with the
demethylating agent. Bisulfite sequencing revealed some aberrant
demethylation in samples treated with SBHA alone (data not
shown); however, this did not result in complete demethylation of
the sample as with 50-aza-20-deoxycytidine. Combination treatment
resulted in a further increase in gene expression; however, this was
not significantly higher compared to the demethylating agent
alone.
DISCUSSION
In this study we show that human CRC cell lines have variable
levels of EphA1 expression. To validate the use of qPCR in tumour
samples, we used these lines to show that mRNA expression
correlated closely with protein expression (Figure 1A and B).
When 125 CRC samples were compared with a set of 18 normal
colon samples a significant increase in EphA1 expression was seen
in the majority of CRC samples. However, all stages contained
some samples with reduced expression compared with the
normals. To make a more precise comparison of tumour with
normal tissue, we obtained 53 paired normal and malignant CRCs
cases. The heterogeneity of expression was confirmed in these
samples with over half showing significantly increased expression
compared with paired normal and most of the remainder showing
significantly decreased expression compared to paired normal. As
with cell lines, EphA1 mRNA levels correlated with protein levels
as determined by immunohistochemistry. In seeking to under-
stand this biphasic expression pattern, we found that reduced
EphA1 expression was more frequent in late-stage CRCs (stage III
vs stage II), suggesting that there was a selective loss of expression
during tumour progression. In support of this notion, patients
with low EphA1 expressing tumours had significantly shorter
survival than the high EphA1 group.
We had previously shown that reduced expression of EphA3 in
haematological tumours was linked to promoter methylation
(Dottori et al, 1999). As with EphA3, the EphA1 gene was shown
to have a CpG island encompassing the 50 end of the gene. We
showed that the CpG island was significantly hypermethylated in
low EphA1 expressing CRCs. Methylation of the 30 end of the CpG
island was even more significant. The re-expression of EphA1
upon treatment with a demethylation agent suggests that
methylation has a regulatory function in EphA1 expression.
Conservation of EphA1 across species raise the possibility that
this 30 region of the CpG island harbours key regulatory elements
of the EphA1 gene. Notwithstanding contributions by other
mechanisms, such as loss of heterozygosity, these data indicate
that control of gene expression by methylation is a major
mechanism of silencing of EphA1.
Our data show that EphA1 over-expression is commonly seen in
locally invasive CRC but that downregulation is more frequent in
metastatic CRC, in many cases mediated through epigenetic gene
silencing. A similar phenomenon has been described for EphB2,
where the loss of expression was associated with cancer progres-
sion (Batlle et al, 2005; Lugli et al, 2005; Guo et al, 2006), and
higher EphB2 expression was associated with prolonged survival
(Guo et al, 2006). More recently, EphB2 was reported to be
inactivated through promoter hypermethylation in a subset of
CRCs (Alazzouzi et al, 2005). EphB1 downregulation was also
observed in pooled CRCs (Hafner et al, 2004). Similarly, there is
emerging evidence to suggest that EphA RTK may also be down-
regulated in other malignancies. A recent study demonstrated
significant downregulation of EphA1 in basal cell and squamous
Exon1
EphA1 CpG island
CpG sites 1–22
5 ′ UTR ATG
CpG sites 1–14 
Figure 5 Genomic structure and localisation of the CpG regions of
EphA1. The CpG sites are indicated by vertical bars. The methylation status
of the 22 CpG sites within the CpG island and the 14 CpG sites located in
the CpG-rich 50-CG-rich region were assessed using bisulfite sequencing.
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inhibitor (suberic bishydroxamate, SBHA) for 24, 48 and 72h. (A) Methylation status of the EphA1 CpG island following treatment as verified by sequencing.
(B) EphA1 mRNA expression quantitated by real-time PCR following treatment. (C) EphA1 protein levels determined by FACS analysis following
treatment.
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Figure 7 Pathway in colorectal cancer (CRC) progression from normal colon to late-stage cancer.
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scell carcinomas, through immunohistochemistry (Hafner et al,
2006). Kataoka et al (2004) demonstrated that EphA2 and ephrin
A1 expression in CRC was associated with clinicopathological
parameters. Both genes were significantly over-expressed in stages
I and II; however, this was less apparent in stages III and IV,
suggesting that loss of these genes is important in the progression
of late-stage CRCs (Kataoka et al, 2004). Interestingly, decreased
EphA7 and EphA6 expression has been reported in pooled CRCs
compared to normal colon (Hafner et al, 2004). This finding was
confirmed in CRCs where epigenetic silencing was shown to be
associated with the downregulation of EphA7 (Wang et al, 2005).
An interesting observation emerging from these studies is the
likely potential for these genes to have separate yet overlapping
function in CRCs. Our data and other studies suggest that one or
more of the Eph genes, in particular, EphA1, EphA2, EphB1, EphB2
and EphB4, are upregulated and may have an oncogenic function
in the early stages of malignant transformation in the colon
(Figure 7). Subsequent gene silencing through methylation and/or
somatic genetic changes may be important in facilitating tumour
migration/invasion. Given the direct correlation between loss of
EphA1 expression and the progression of CRC to a more invasive
phenotype, EphA1 appears to be a potentially valuable marker,
particularly as part of algorithms for defining those patients with a
poor prognosis.
Eph proteins have been identified as therapeutic targets in
cancer, both as anti-cancer and anti-angiogenic agents. Several
therapeutic candidates including antibodies to EphA2 (Landen
et al, 2005), EphA3 (Vearing et al, 2005) and EphB2 (Mao et al,
2004) are in advanced pre-clinical or early clinical assessment.
Although therapies targeting the high EphA1 expression in early
phase CRC seem logical, the loss of expression in advanced disease
poses the risk that targeted therapies may select for loss of
expression and thus contribute to disease progression. Recognis-
ing the surprising biphasic pattern of EphA1 expression during
CRC progression, and potentially in other epithelial tumours,
requires a careful evaluation of the function of Eph expression in
CRC and their rational targeting with Eph-specific therapies.
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